Ambrisentan

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 510 publications

A Rare Case of Pulmonary Arterial Hypertension in a Patient With Breast Cancer Treated With Trastuzumab Emtansine.

A Rare Case of Pulmonary Arterial Hypertension in a Patient With Breast Cancer Treated With Trastuzumab Emtansine.

Journal: Cureus

Published: May 17, 2026

Modulation of ET1/NF-κB/IL-6/STAT-4/AP-1 pathway by ambrisentan alleviates isoprenaline-induced myocardial injury.

Modulation of ET1/NF-κB/IL-6/STAT-4/AP-1 pathway by ambrisentan alleviates isoprenaline-induced myocardial injury.

Journal: Immunopharmacology and immunotoxicology

Published: May 15, 2026

Ambrisentan Exhibits Hepatoprotective Effects Against NASH-Associated Hepatic Injury in Dexamethasone-Treated Rats Through Regulation of Inflammation, Ferroptosis and Autophagy.

Ambrisentan Exhibits Hepatoprotective Effects Against NASH-Associated Hepatic Injury in Dexamethasone-Treated Rats Through Regulation of Inflammation, Ferroptosis and Autophagy.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: April 16, 2026

A Rare Case of Multi-System Involvement and Hereditary Pulmonary Hypertension Caused by De Novo Heterozygous CAV1 Mutation in a Pediatric Patient.

A Rare Case of Multi-System Involvement and Hereditary Pulmonary Hypertension Caused by De Novo Heterozygous CAV1 Mutation in a Pediatric Patient.

Journal: Children (Basel, Switzerland)

Published: April 13, 2026

Evidence Gap and Challenges in the Management of Mild Pulmonary Hypertension.

Evidence Gap and Challenges in the Management of Mild Pulmonary Hypertension.

Journal: JACC. Asia

Published: March 19, 2026

Marked clinical and haemodynamic improvement with sotatercept in severe refractory pulmonary arterial hypertension associated with corrected complex congenital heart disease.

Marked clinical and haemodynamic improvement with sotatercept in severe refractory pulmonary arterial hypertension associated with corrected complex congenital heart disease.

Journal: Respiratory medicine case reports

Published: January 22, 2026

Pulmonary Artery Denervation for Refractory Sjögren's Syndrome-Associated Pulmonary Arterial Hypertension: A Case Report of Combined Hemodynamic and Renal Recovery.

Pulmonary Artery Denervation for Refractory Sjögren's Syndrome-Associated Pulmonary Arterial Hypertension: A Case Report of Combined Hemodynamic and Renal Recovery.

Journal: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

Published: December 09, 2025

Ambrisentan attenuates cisplatin-related mitochondrial dysfunction in the heart via regulation of p53 and NF-κB signaling.

Ambrisentan attenuates cisplatin-related mitochondrial dysfunction in the heart via regulation of p53 and NF-κB signaling.

Journal: Scientific reports

Published: October 30, 2025

Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy: A Randomized Crossover Trial.

Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy: A Randomized Crossover Trial.

Journal: Journal of the American Society of Nephrology : JASN

Published: October 10, 2025

Breath-activated nanomedicine: Ambrisentan-loaded chitosomes for pulmonary arterial hypertension.

Breath-activated nanomedicine: Ambrisentan-loaded chitosomes for pulmonary arterial hypertension.

Journal: International journal of pharmaceutics

Published: October 06, 2025

Endothelin-1 in the failing Fontan: pathobiology, precision therapeutics, and future trial design.

Endothelin-1 in the failing Fontan: pathobiology, precision therapeutics, and future trial design.

Journal: Frontiers in pediatrics

Published: October 03, 2025

Disproportionality analysis of adverse events associated with endothelin receptor antagonists based on the FDA adverse event reporting system (FAERS).

Disproportionality analysis of adverse events associated with endothelin receptor antagonists based on the FDA adverse event reporting system (FAERS).

Journal: Frontiers in cardiovascular medicine

Published: September 25, 2025

Showing 1-12 of 510

Last Updated: 06/30/2026